The concept of adoptive immunotherapy (AIT) for cancer treatment was presented by Mule et al22 in the form of IL‐2 generated lymphokine‐activated killer (LAK) cells combined with repeated injections of recombinant IL‐2 (Table 1). The gene discussed is IL2; the disease is cancer.